JAK1


Also found in: Acronyms.

JAK1

A gene on chromosome 1p32.3-p31.3 that encodes a non-receptor protein tyrosine kinase involved in the IFN-alpha/beta/gamma signal pathway, which is further characterised by a second phosphotransferase-related domain immediately N-terminal to the PTK domain.
References in periodicals archive ?
Safety and efficacy of INCBO18424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
We also remain very encouraged about the recent progress we've made with our late-stage pipeline, including strong results from a registrational trial of our selective JAK1 inhibitor, upadacitinib.
STAT3 suppression was mediated through the inhibition of activation of upstream JAK2, but not of JAK1 and Src kinases.
July 30 (SeeNews) - Belgium-based biotechnology firm Galapagos (AMS:GLPG) said Wednesday the selective JAK1 inhibitor filgotinib
Its lead product is CYT387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of hematological and immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers.
A faster-acting compound called oclacitinib has shown promise based on its high affinity for inhibiting JAK1 enzyme-mediated activation of cytokine expression, including interleukin (IL)-31, he said.
According to the companies, Baricitinib is a once-daily oral JAK inhibitor and are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2.
April 28 (SeeNews) - Belgian biotechnology firm Galapagos (AMS:GLPG) said Monday its selective JAK1 inhibitor filgotinib had met key efficacy
AbbVie's continued progress across our upadacitinib clinical development program further demonstrates that selective inhibition of the JAK1 pathway may be a novel therapeutic approach across a broad range of immune-mediated diseases.
Chen and his associates modeled the molecular mechanisms of action of the pan-Janus kinase inhibitor tofacitinib, the JAK1 /JAK2 inhibitor ruxolitinib, the CTLA4 inhibitor abatacept, and intralesional triamcinolone acetonide (IL-TAC).
The trial, GRAVITAS-301 (NCT03139604), will assess the efficacy and safety of Itacitinib (INCB039110), the company's novel, potent, and selective JAK1 inhibitor.